Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications

View Full Paper

Ask AI

Bookmark

High lipoprotein(a) levels may indicate a potential link to venous thromboembolism, highlighting the need for further studies.
Current evidence shows that lipoprotein(a) can have atherogenic and antifibrinolytic properties, influencing cardiovascular risk.
Ongoing research is exploring medications aimed at reducing lipoprotein(a) levels, but their impact on venous thromboembolism remains unclear.
Statins, which do not affect lipoprotein(a), have been shown to reduce incident venous thromboembolism, calling for differentiated treatment strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Review outlines the complex relationship between lipoprotein(a) and venous thromboembolism, suggesting further research is needed.

Pfeferman et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark